Innovita Biological Technology (SH:688253) Zheng Quan Zhi Xing·2025-08-29 17:24Meeting Overview - The second board meeting of Beijing Innotech Biotechnology Co., Ltd. was held on August 27, 2025, with all 9 directors present, and the meeting complied with relevant laws and regulations [1]. Financial Reports - The board approved the 2025 semi-annual report and its summary with a unanimous vote of 9 in favor [2]. - The board also approved a special report on the storage and actual use of raised funds for the first half of 2025, confirming compliance with regulations and proper use of funds [2]. Cash Management - The board agreed to use up to RMB 300 million of idle raised funds for cash management, allowing for the purchase of safe and liquid financial products, with a rolling usage period from September 2, 2025, to September 1, 2026 [3]. - Additionally, the board approved the use of up to RMB 1.7 billion of idle self-owned funds for similar cash management purposes during the same period [4]. Stock Incentive Plan - The board approved an adjustment to the grant price of the 2023 restricted stock incentive plan from RMB 13.20 per share to RMB 12.65 per share [5]. - A semi-annual evaluation report on the "Quality Improvement and Efficiency Enhancement" action plan for 2025 was also approved [6]. Corporate Governance Changes - The board approved changes to the registered capital and the cancellation of the supervisory board, allowing the audit committee to assume its responsibilities [7]. - The board agreed to revise and add certain company regulations to enhance governance structure [8]. Fund Allocation - The board approved the use of RMB 60 million of surplus raised funds for the "In Vitro Diagnostic Product R&D Project" and extended the project's timeline by 18 months [10]. Stock Incentive Plan Draft - The board approved the draft of the 2025 restricted stock incentive plan, which aims to attract and retain talent while aligning interests among shareholders, the company, and core team members [11][13]. Authorization for Stock Incentive Plan - The board proposed to seek shareholder authorization for handling matters related to the 2025 restricted stock incentive plan [15]. Insurance for Directors - A proposal for purchasing liability insurance for directors and supervisors was submitted for shareholder approval due to the absence of a valid resolution [17]. Shareholder Meeting - The board approved a proposal to convene the first extraordinary general meeting of shareholders in 2025 [14].